Chan Joshua L, Patel Deven C, Megna Dominick, Dimbil Sadia J, Levine Ryan, Moriguchi Jaime, Czer Lawrence S, Kobashigawa Jon A, Arabia Francisco, Esmailian Fardad
Cedars-Sinai Heart Institute, Los Angeles, CA, USA.
Division of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Interact Cardiovasc Thorac Surg. 2018 Nov 1;27(5):773-777. doi: 10.1093/icvts/ivy156.
Previous studies have demonstrated that preheart transplant mechanical circulatory support (MCS) can lead to a small but significant increase in mortality. However, data on outcomes of patients with MCS who require simultaneous heart-kidney transplant are limited.
A retrospective review of simultaneous heart-kidney transplantations (HKTxs) performed at a single institution over a 5-year period was performed. Patients were divided based on the preoperative use of durable MCS. Renal graft-related end points were evaluated, including glomerular filtration rate following transplantation, prevalence of delayed renal graft function and freedom from antibody and cellular-mediated graft rejection. Patient-specific outcomes, including survival and frequency of non-fatal major adverse cardiac events at 1 year, were additionally assessed.
During the study period, 50 HKTxs were performed, 14 of which had preoperative MCS. HKTx patients with and without MCS implantations had a similar prevalence of delayed graft function (57.1% vs 50.0%; P = 0.757). A numerical trend was observed towards a reduced glomerular filtration rate 1-month post-transplant in patients without an MCS device (81.2 ± 32.8 vs 64.4 ± 27.5; P = 0.072), but no significant difference was observed at 6 and 12 months. No significant difference was observed on the need for post-transplant renal replacement therapy, non-fatal major adverse cardiac events, freedom from graft rejection and overall survival at 1 year.
The use of preoperative MCS in patients undergoing combined HKTx was not found to affect renal graft function post-transplantation and does not seem to be associated with increase in morbidity or mortality.
既往研究表明,心脏移植前机械循环支持(MCS)可导致死亡率小幅但显著上升。然而,关于需要同时进行心脏-肾脏移植的MCS患者预后的数据有限。
对某单一机构在5年期间进行的同期心脏-肾脏移植(HKTx)进行回顾性研究。根据术前是否使用持久性MCS对患者进行分组。评估肾脏移植相关终点,包括移植后肾小球滤过率、移植肾功能延迟恢复的发生率以及无抗体和细胞介导的移植排斥反应。此外,还评估了患者特异性结局,包括1年时的生存率和非致命性主要不良心脏事件的发生率。
在研究期间,共进行了50例HKTx,其中14例术前接受了MCS。接受和未接受MCS植入的HKTx患者移植肾功能延迟恢复的发生率相似(57.1%对50.0%;P = 0.757)。未使用MCS装置的患者在移植后1个月时肾小球滤过率有下降的数值趋势(81.2±32.8对64.4±27.5;P = 0.072),但在6个月和12个月时未观察到显著差异。在移植后肾脏替代治疗的需求、非致命性主要不良心脏事件、无移植排斥反应以及1年时的总体生存率方面未观察到显著差异。
在接受联合HKTx的患者中,术前使用MCS未发现会影响移植后的肾功能,且似乎与发病率或死亡率的增加无关。